{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:59:15Z","timestamp":1793383155085,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,6,11]],"date-time":"2013-06-11T00:00:00Z","timestamp":1370908800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s00467-013-2490-z","type":"journal-article","created":{"date-parts":[[2013,6,10]],"date-time":"2013-06-10T01:58:15Z","timestamp":1370829495000},"page":"1837-1842","source":"Crossref","is-referenced-by-count":13,"title":["Alport syndrome: the effects of spironolactone on proteinuria and urinary TGF-\u03b21"],"prefix":"10.1007","volume":"28","author":[{"given":"Marisa","family":"Giani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Mastrangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Turolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amedea Silvia","family":"Tirelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Hopfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Edefonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,11]]},"reference":[{"key":"2490_CR1","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1126\/science.2349482","volume":"248","author":"DF Barker","year":"1990","unstructured":"Barker DF, Hostikka SL, Zhou J, Chow LT, Oliphant AR, Gerken SC, Gregory MC, Skolnick MH, Atkin CL, Tryggvason K (1990) Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science 248:1224\u20131227","journal-title":"Science"},{"key":"2490_CR2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/ki.1995.163","volume":"47","author":"MC Gubler","year":"1995","unstructured":"Gubler MC, Knebelmann B, Beziau A, Broyer M, Pirson Y, Haddoum F, Kleppel MM, Antignac C (1995) Autosomal recessive Alport syndrome: immunohistochemical study of type IV collagen chain distribution. Kidney Int 47:38\u201344","journal-title":"Kidney Int"},{"key":"2490_CR3","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3109\/08860220903150312","volume":"31","author":"I Guney","year":"2009","unstructured":"Guney I, Selcuk YN, Altintepe L, Atalay H, Ba\u015farali KM, B\u00fcy\u00fckba\u015f S (2009) Antifibrotic effects of aldosterone receptor blocker (Spironolactone) in patients with chronic kidney disease. Ren Fail 31:779\u2013784","journal-title":"Ren Fail"},{"key":"2490_CR4","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbrc.2006.07.057","volume":"348","author":"L Lai","year":"2006","unstructured":"Lai L, Chen J, Hao CM, Lin S, Gu Y (2006) Aldosterone promotes fibronectin production through a Smad2-dependent TGF-\u03b21 pathway in mesangial cells. Biochem Biophys Res Commun 348:70\u201375","journal-title":"Biochem Biophys Res Commun"},{"key":"2490_CR5","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/ndt\/17.12.2145","volume":"17","author":"DS Goumenos","year":"2002","unstructured":"Goumenos DS, Tsakas S, El Nahas AM, Alexandri S, Oldroyd S, Kalliakmani P, Vlachojannis JG (2002) Transforming growth factor-\u03b21 in the kidney and urine of patients with glomerular disease and proteinuria. Nephrol Dial Transplant 17:2145\u20132152","journal-title":"Nephrol Dial Transplant"},{"key":"2490_CR6","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1097\/01.ASN.0000090034.71205.74","volume":"14","author":"JP Jais","year":"2003","unstructured":"Jais JP, Knebelmann B, Giartis I, De Marchi M, Rizzoni G, Renieri A, Weber M, Gross O, Netzer KO, Flinter F, Pirson Y, Dahan K, Wieslander J, Persson U, Tryggvason K, Martin P, Hertz JM, Schr\u00f6der C, Sanak M, Carvalho MF, Saus J, Antignac C, Smeets H, Gubler MC (2003) X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a \u201cEuropean Community Alport Syndrome Concerted Action\u201d study. J Am Soc Nephrol 14:2603\u20132610","journal-title":"J Am Soc Nephrol"},{"key":"2490_CR7","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/ki.2009.223","volume":"76","author":"O Gross","year":"2009","unstructured":"Gross O, Kashtan CE (2009) Treatment of Alport syndrome: beyond animal models. Kidney Int 76:599\u2013603","journal-title":"Kidney Int"},{"key":"2490_CR8","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/01.ASN.0000046964.15831.16","volume":"14","author":"D Chen","year":"2003","unstructured":"Chen D, Jefferson B, Harvey SJ, Gartley CJ, Jacobs RM, Thorner PS (2003) Cyclosporine A slows the progressive renal disease of Alport syndrome (X-linked Hereditary Nephritis): results from a canine model. J Am Soc Nephrol 14:690\u2013698","journal-title":"J Am Soc Nephrol"},{"key":"2490_CR9","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00467-010-1484-3","volume":"25","author":"L Massella","year":"2010","unstructured":"Massella L, Onetti Muda A, Legato A, Di Zazzo G, Giannakakis K, Emma F (2010) Cyclosporine A treatment in patients with Alport syndrome: a single-center experience. Pediatr Nephrol 25:1269\u20131275","journal-title":"Pediatr Nephrol"},{"key":"2490_CR10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00467-006-0227-y","volume":"22","author":"M Charbit","year":"2007","unstructured":"Charbit M, Gubler MC, Dechaux M, Gagnadoux MF, Gr\u00fcnfeld JP, Niaudet P (2007) Cyclosporine therapy in patients with Alport syndrome. Pediatr Nephrol 22:57\u201363","journal-title":"Pediatr Nephrol"},{"key":"2490_CR11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00467-003-1366-z","volume":"19","author":"W Proesmans","year":"2004","unstructured":"Proesmans W, Van Dyck M (2004) Enalapril in children with Alport syndrome. Pediatr Nephrol 19:271\u2013275","journal-title":"Pediatr Nephrol"},{"key":"2490_CR12","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1093\/ndt\/gfq797","volume":"26","author":"NJ Webb","year":"2011","unstructured":"Webb NJ, Lam C, Shahinfar S (2011) Efficacy and safety of losartan in children with Alport syndrome \u2013 results from a subgroup analysis of prospective, randomized, placebo- or amlodipine-controlled trial. Nephrol Dial Transplant 26:2521\u20132526","journal-title":"Nephrol Dial Transplant"},{"key":"2490_CR13","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/ki.2011.407","volume":"81","author":"O Gross","year":"2012","unstructured":"Gross O, Licht C, Anders HJ (2012) Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 81:494\u2013501","journal-title":"Kidney Int"},{"key":"2490_CR14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(03)12229-5","volume":"361","author":"N Nakao","year":"2003","unstructured":"Nakao N, Yoshimura A (2003) Combination treatment of angiotensin II receptor blocker and angiotensin-converting-enzyme inhibitor in non diabetic renal disease. Lancet 361:117\u2013124","journal-title":"Lancet"},{"key":"2490_CR15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1291\/hypres.31.59","volume":"31","author":"Y Furumatsu","year":"2008","unstructured":"Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T (2008) Effect of Renin-Angiotensin-Aldosterone system triple blockade on non-diabetic renal disease: addition of aldosterone blocker, Spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res 31:59\u201367","journal-title":"Hypertens Res"},{"key":"2490_CR16","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1016\/j.transproceed.2010.08.024","volume":"42","author":"E Gonz\u00e1lez Monte","year":"2010","unstructured":"Gonz\u00e1lez Monte E, Andr\u00e9s A, Polanco N, Toribio ML, Santana R, Guti\u00e9rrez Mart\u00ednez E, Gonz\u00e1lez J, Ram\u00edrez E, Hern\u00e1ndez A, Morales E, Praga M, Morales JM (2010) Addition of spironolactone to dual blockade of renina angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6\u00a0months. Transplant Proc 42:2899\u20132901","journal-title":"Transplant Proc"},{"key":"2490_CR17","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00467-006-0270-8","volume":"21","author":"H Kaito","year":"2006","unstructured":"Kaito H, Nozu K, Iijima K, Nakanishi K, Yoshiya K, Kanada K, Przybyslaw Krol R, Yoshikawa N, Matsuo M (2006) The effect of aldosterone blockade in patients with Alport syndrome. Pediatr Nephrol 21:1824\u20131829","journal-title":"Pediatr Nephrol"},{"key":"2490_CR18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00467-012-2138-4","volume":"28","author":"CE Kashtan","year":"2013","unstructured":"Kashtan CE, Ding J, Gregory M, Gross O, Heidet L, Knebelmann B, Rheault M, Licht C (2013) Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatr Nephrol 28:5\u201311","journal-title":"Pediatr Nephrol"},{"key":"2490_CR19","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0031-3955(16)36251-4","volume":"34","author":"GJ Schwartz","year":"1987","unstructured":"Schwartz GJ, Brion LP, Spitzer A (1987) The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 34:571\u2013590","journal-title":"Pediatr Clin North Am"},{"key":"2490_CR20","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","volume":"70","author":"S Bianchi","year":"2006","unstructured":"Bianchi S, Bigazzi R, Campese VM (2006) Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 70:2116\u20132123","journal-title":"Kidney Int"},{"key":"2490_CR21","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/ndt\/gfg090","volume":"18","author":"HC Park","year":"2003","unstructured":"Park HC, Xu ZG, Choi S, Goo YS, Kang SW, Choi KH, Ha SK, Lee HY, Han DS (2003) Effect of losartan and amlodipine on proteinuria and transforming growth factor-\u03b21 in patients with IgA nephropathy. Nephrol Dial Transplant 18:1115\u20131121","journal-title":"Nephrol Dial Transplant"},{"key":"2490_CR22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/eurheartj\/16.suppl_N.103","volume":"16","author":"AD Struthers","year":"1995","unstructured":"Struthers AD (1995) Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J 16:103\u2013106","journal-title":"Eur Heart J"},{"key":"2490_CR23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1254\/jphs.FMJ05003X3","volume":"100","author":"A Nishiyama","year":"2006","unstructured":"Nishiyama A, Abe Y (2006) Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade. J Pharmacol Sci 100:9\u201316","journal-title":"J Pharmacol Sci"},{"key":"2490_CR24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000093178","volume":"26","author":"S Tsakas","year":"2006","unstructured":"Tsakas S, Goumenos DS (2006) Accurate measurement and clinical significance of urinary transforming growth factor-beta1. Am J Nephrol 26:186\u2013193","journal-title":"Am J Nephrol"},{"key":"2490_CR25","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/ndt\/gfg090","volume":"18","author":"H Cheon Park","year":"2003","unstructured":"Cheon Park H, Gao Xu Z, Choi S, Young SG, Wook Kang S, Hun Choi K, Kyu Ha S, Lee Y, Suk Han D (2003) Effect of losartan and amlodipine on proteinuria and transforming growth factor-\u03b21 in patients with IgA nephropathy. Nephrol Dial Transplant 18:1115\u20131121","journal-title":"Nephrol Dial Transplant"},{"key":"2490_CR26","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1046\/j.1523-1755.1999.00744.x","volume":"56","author":"R Sayers","year":"1999","unstructured":"Sayers R, Kalluri R, Rogers KD, Shiel CF, Meehan DT, Cosgrove D (1999) Role for transforming growth factor-beta1 in Alport renal disease progression. Kidney Int 56:1662\u20131673","journal-title":"Kidney Int"},{"key":"2490_CR27","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0002-9440(10)64802-X","volume":"157","author":"D Cosgrove","year":"2000","unstructured":"Cosgrove D, Rodgers K, Meehan D, Miller C, Bovard K, Gilroy A, Gardner H, Kotelianski V, Gotwals P, Amatucci A, Kalluri R (2000) Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in Alport glomerular pathogenesis and serve as dual targets for metabolic therapy. Am J Pathol 157:1649\u20131659","journal-title":"Am J Pathol"},{"key":"2490_CR28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2369-3-2","volume":"3","author":"L Adler","year":"2002","unstructured":"Adler L, Mathew R, Futterweit S, Frank R, Gauthier BG, Kashtan CE, Trachtman H (2002) Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-\u03b2, and nitrite excretion. BMC Nephrol 3:2\u20137","journal-title":"BMC Nephrol"},{"key":"2490_CR29","doi-asserted-by":"crossref","first-page":"F2","DOI":"10.1152\/ajprenal.00072.2007","volume":"293","author":"NA Bobadilla","year":"2007","unstructured":"Bobadilla NA, Gamba G (2007) New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone. Am J Physiol Renal Physiol 293:F2\u2013F9","journal-title":"Am J Physiol Renal Physiol"},{"key":"2490_CR30","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00467-011-1868-z","volume":"27","author":"D Cosgrove","year":"2012","unstructured":"Cosgrove D (2012) Glomerular pathology in Alport syndrome: a molecular prospective. Pediatr Nephrol 27:885\u2013890","journal-title":"Pediatr Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-013-2490-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-013-2490-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-013-2490-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T01:10:39Z","timestamp":1563153039000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-013-2490-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,11]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["2490"],"URL":"https:\/\/doi.org\/10.1007\/s00467-013-2490-z","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,11]]}}}